Reply to letters on review ‘Evolving treatment strategies for myeloma'
2005
Reply to letters on review ‘Evolving treatment strategies for myeloma'
publication
Evidence: low
Author Information
Author(s): G J Morgan, F E Davies
Primary Institution: Royal Marsden Hospital and Institute of Cancer Research
Conclusion
The antitumour effect of bisphosphonates in myeloma is not yet proven in vivo, and their use should be based on their ability to inhibit bone resorption and reduce skeletal-related events.
Supporting Evidence
- Bisphosphonates have shown antimyeloma effects only in cell lines and mouse models.
- The only clear proof that temperature is related to myeloma is that it resolves with antimyeloma treatment.
- All patients should receive a bisphosphonate due to its dramatic effects on skeletal-related events.
Takeaway
Doctors are discussing how to treat myeloma patients who have fevers and whether certain medications can help fight the disease, but more research is needed.
Limitations
The in vivo antimyeloma effect of bisphosphonates is not yet established, and the relevance of their mechanisms in myeloma plasma cells is uncertain.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website